ARS Pharmaceuticals investors face Oct. 5 lead-plaintiff deadline after 23.9% stock drop
AI Summary- Faruqi & Faruqi is investigating alleged securities-law violations by ARS Pharmaceuticals.
- ARS shares fell $2.52, or 23.9%, to $8.02 on June 25, 2026.
- Investors purchased securities during the stated class period may seek lead-plaintiff appointment by October 5, 2026.